Michael Derks

Michael Derks

Auto-generated profile, based on publicly available information

Michael Derks

F. Hoffmann-La Roche Ltd, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MDMichael Derks
Michael Derks
MAMarkus Abt
Markus Abt
MPMary Phelan
Mary Phelan
LTLynn Turnbull
Lynn Turnbull
GMGeorgina Meneses‐Lorente
Georgina Meneses‐Lorente
GPGraeme Parr
Graeme Parr


26 August 2010 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
MDMichael Derks
Michael Derks
MAMarkus Abt
Markus Abt
GPGraeme Parr
Graeme Parr
GMGeorgina Meneses-Lorente
Georgina Meneses-Lorente
AYAnne-Marie Young
Anne-Marie Young
MPMary Phelan
Mary Phelan
(2010). No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs: Vol. 19, No. 10, pp. 1135-1145. doi: 10.1517/13543784.2010.509342

26 February 2009 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
MDMichael Derks
Michael Derks
SFStephen Fowler
Stephen Fowler
OKOlaf Kuhlmann
Olaf Kuhlmann
Objective: The primary objective of this study was to investigate the drug–drug interaction potential of dalcetrapib on drugs metabolized via major cytochrome P450 (CYP) isoforms using both in vitro and clinical approaches. A secondary objective was to investigate the safety and tolerability of dalcetrapib alone or co-administered either with a combination of five probe drugs or with rosiglitazone. Research design and methods: Human liver microsomes and a panel of substrates for CYP enzymes were used to determine IC50 for inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. In addition, two drug–drug interaction studies were conducted in healthy males: dalcetrapib 900 mg plus the Cooperstown 5 + 1 drug cocktail, which includes substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and dalcetrapib 900 mg plus rosiglitazone, a substrate for CYP2C8. Pharmacokinetic and safety parameters were assessed. Results: In vitro, dalcetrapib was inhibitory to all CYP enzymes tested. IC50 values ranged from 1.5 ± 0.1 μM for CYP2C8 to 82 ± 4 μM for CYP2D6. Co-administration of dalcetrapib plus drug cocktail showed no clinically relevant effect of 900 mg dalcetrapib on activity of CYP1A2, CYP2C19, CYP2D6, CYP2C9, or CYP3A4 following repeated administration. Co-administration of dalcetrapib plus rosiglitazone showed no clinically relevant effect of dalcetrapib 900 mg on activity of CYP2C8. Dalcetrapib was generally well tolerated. Conclusions: Although in vitro studies indicated that dalcetrapib inhibits CYP activity, two clinical studies showed no clinically relevant effect on any of the major CYP isoforms at a 900 mg dose, which is higher than the 600 mg dose being explored in phase III studies. Dalcetrapib was generally well tolerated in these studies. However, these studies were limited to a small number of healthy males; additional, larger studies are necessary to study its safety.

1 May 2011 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
MDMichael Derks
Michael Derks
JAJudith Anzures-Cabrera
Judith Anzures-Cabrera
LTLynn Turnbull
Lynn Turnbull
MPMary Phelan
Mary Phelan

3 June 2010 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MDMichael Derks
Michael Derks
MAMarkus Abt
Markus Abt
AMAnne Mwangi
Anne Mwangi
GMGeorgina Meneses-Lorente
Georgina Meneses-Lorente